Phytochemical screening and Gas chromatography-mass spectrometry analysis on Ischaemumpilosum (Kleinex Willd.)

Ischaemumpilosum (Kleinex Willd.) a weed among the grass is reported for ethno-medicinal practices for treatment of various treatments for human and domestic animals. The current work deals with phytochemical analysis in different parts of plants to find out bioactive compounds. The first-time reported results onI. pilosumreveal the significant phytochemicals by using preliminary phytochemical analysis, UV Visible spectral technique, FTIR analysis and GC-MS analysis. The preliminary phytochemical test confirms the presence of alkaloids, anthraquinone, cardiac glycosides, coumarins, flavonoids, glycosides, phenols, reducing sugars, saponins, steroids, tannin and triterpenes in Ischaemumpilosum.UV Visible spectra and FTIR gives the ranges of absorptions and functional group like Carboxylic acids (O-H) at 2956,92 cm-1, Alkanes (O-H) at 2849,89 cm-1, Aldehydes (C=O) at 1735,92 cm-1, Aromatic Rings (C=C) at 1462,95 cm-1, Alkanes (C-H) at 1377,97 cm-1, Esters (C-O) 1166,95 cm-1and Phenyl Ring (C-H) 758,97 cm-1. The GC-MS analysis related twenty-one compounds like Phenol, 4-bis (1,1-dimethylethyl), Pentanoic acid, 5-hydroxy, 2,4-di-t-butylphenyl esters, E-15-Heptadecenal, 1-Hexadecanol, n-Hexadecanoic acid, l (+)-Ascorbic acid 2,6-dihexadecanoate, Palmitic anhydride, Cycloeicosane, Cis-13-Octadecenoic acid and Triacontane from Ischaemumpilosumleaves extract

Late gastrointestinal tissue effects after hypofractionated radiation therapy of the pancreas

Background To consolidate literature reports of serious late gastrointestinal toxicities after hypofractionated radiation treatment of pancreatic cancer and attempt to derive normal tissue complication probability (NTCP) parameters using the Lyman-Kutcher-Burman model. Methods Published reports of late grade 3 or greater gastrointestinal toxicity after hypofractionated treatment of pancreatic cancer were reviewed. The biologically equivalent dose in 1.8 Gy fractions was calculated using the EQD model. NTCP parameters were calculated using the LKB model assuming 1–5 % of the normal tissue volume was exposed to the prescription dose with α/β ratios of 3 or 4. Results A total of 16 human studies were examined encompassing a total of 1160 patients. Toxicities consisted of ulcers, hemorrhages, obstructions, strictures, and perforations. Non-hemorrhagic and non-perforated ulcers occurred at a rate of 9.1 % and were the most commonly reported toxicity. Derived NTCP parameter ranges were as follows: n = 0.38–0.63, m = 0.48–0.49, and TD50 = 35–95 Gy. Regression analysis showed that among various study characteristics, dose was the only significant predictor of toxicity. Conclusions Published gastrointestinal toxicity reports after hypofractionated radiotherapy for pancreatic cancer were compiled. Median dose was predictive of late grade ≥ 3 gastrointestinal toxicity. Preliminary NTCP parameters were derived for multiple volume constraints

Electrochemically synthesized polymers in molecular imprinting for chemical sensing

This critical review describes a class of polymers prepared by electrochemical polymerization that employs the concept of molecular imprinting for chemical sensing. The principal focus is on both conducting and nonconducting polymers prepared by electropolymerization of electroactive functional monomers, such as pristine and derivatized pyrrole, aminophenylboronic acid, thiophene, porphyrin, aniline, phenylenediamine, phenol, and thiophenol. A critical evaluation of the literature on electrosynthesized molecularly imprinted polymers (MIPs) applied as recognition elements of chemical sensors is presented. The aim of this review is to highlight recent achievements in analytical applications of these MIPs, including present strategies of determination of different analytes as well as identification and solutions for problems encountered

Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

peer reviewedThe authors regret that at the time the article was published, Supplementary Table S2 contained errors. This has now been corrected. The authors would like to apologise for any inconvenience caused